PBPH ETF Analysis: Portfolio Building Block | NASDAQ
Health | NASDAQ, USA | Market Cap: 935m USD | 12M Return: 9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.09M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality
The Invesco Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) is a passively managed fund listed on NASDAQ that seeks to replicate the performance of its underlying index, before fees and expenses. The index is built using a rules-based methodology that screens for pharmaceutical and biotechnology companies whose ordinary shares trade on major developed-market stock exchanges, with classifications provided by index provider BITA GmbH. Under normal market conditions, the fund commits at least 80% of its net assets to the indexs component securities, and it operates as a non-diversified fund. As a sector-specific ETF, PBPH offers targeted exposure to the healthcare subsectors of drug development, manufacturing, and biotechnology research, areas characterized by long product cycles, heavy R&D spending, and sensitivity to regulatory approvals and patent expirations.
- FDA drug approval pace drives constituent company revenue growth
- Patent cliff exposure pressures major pharma profit margins
- Federal Reserve rate cuts lift biotech valuations across portfolio holdings
As of July 28, 2026, the stock is trading at USD 27.52 with a total of 76,361 shares traded. Over the past week, the price has changed by +2.94%, over one month by +0.30%, over three months by +12.20% and over the past year by +8.99%.
Current recommended Stop Loss: 26.70 (which is 3% or 2.1 ATR below the current price).
Portfolio Building Block has no consensus analysts rating.